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Abstract: Anemia, iron deficiency and other hematinic deficiencies are a major cause of periopera-
tive transfusion needs and are associated with increased morbidity and mortality. Anemia can be 
caused either by decreased production of hemoglobin or red blood cells or by increased consump-
tion and blood loss. Decreased production can involve anything from erythropoietin or vitamin B12 
insufficiency to absolute or functional lack of iron. Thus, to achieve the goal of patient blood man-
agement, anemia must be addressed by addressing its causes. The traditional parameters to diag-
nose anemia, despite offering elaborate options, are not ideally suited to giving a simple overview 
of the causes of anemia, e.g., iron status for erythropoiesis, especially during the acute phase of 
inflammation, acute blood loss or iron deficiency. Reticulocyte hemoglobin can thus help to uncover 
the cause of the anemia and to identify the main factors inhibiting erythropoiesis. Regardless of the 
cause of anemia, reticulocyte hemoglobin can also quickly track the success of therapy and, together 
with the regular full blood count it is measured alongside, help in clearing the patient for surgery. 
Keywords: Anemia; iron deficiency; Patient Blood Management; Reticulocyte hemoglobin (Ret He); 
anemia of inflammation (ACD; anemia of chronic decease); hospital acquired anemia 
1. Introduction
“Patient Blood Management” (PBM) and “Enhanced Recovery After Surgery” 
(ERAS) concepts are systematic quality improving clinical models. One major part is to 
diagnose and reduce anemia and avoid transfusions in all kinds of clinical settings. Here, 
we review the potential of Reticulocyte and Erythrocyte Hemoglobin Parameters for Iron 
Deficiency and Anemia Diagnostics in these more and more important clinical concepts. 
The ERAS concept is a set of evidence-based practices which aim to optimize out-
come, reduce patient surgical stress response, and improve recovery after surgery [1–3]. 
ERAS strives to optimize each patient’s condition, from preoperative, intraoperative and 
postoperative hospital intensive care treatment all the way to the post-discharge phase. 
This is achieved through patient education, preparation, and physiological optimization, 
including additional medical interventions as needed. It has been shown that even in the 
absence of full adherence, the closer practice is to ERAS standards, the fewer postopera-
tive complications are observed and the shorter the hospitalization period needed [4,5]. 
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When successfully implemented, ERAS can reduce morbidity by 50% and length of stay 
by 2.5 days, without an increase in readmissions [6]. This is not only beneficial for the 
patient, but also helps reduce costs and save resources, without cutting corners or putting 
patients at risk. 
2. Patient Blood Management in the ERAS Concept 
One important and modifiable factor affecting patients undergoing surgery is pre-
operative anemia. It affects more than a third of patients undergoing major surgery [7]. 
But even without manifest anemia, iron deficiency is an independent risk factor of worse 
outcomes [7]. Anemia, iron deficiency and other hematinic deficiencies are thus a major 
cause of transfusion needs and are associated with increased morbidity and mortality [7–
10]. 
Iron deficiency is a major cause of preoperative anemia. But iron or other hematinic 
deficiencies need to be treated because they not only interfere with preoperative anemia 
therapy such as erythropoiesis stimulating agent (ESA) treatment, which is less effective 
when the iron supply is absent or insufficient, but also prevent postoperative recovery. 
Any blood loss because of surgery only exacerbates the problem, leading to postoperative 
anemia being even more common [11,12] and iron deficiency at all stages leads to a higher 
risk of complications. 
As Anemia and iron deficiency are clinical problems that can be resolved prior to 
surgery, they are among the factors addressed by the ERAS concept. Patient blood man-
agement (PBM) is thus an important part of the ERAS concept and focuses on optimizing 
the care of patients who might need a blood transfusion [13]. 
The most immediate medical intervention used to counter anemia is the administra-
tion of packed red blood cells. However, use of blood products is associated with a sub-
stantial risk of complications and morbidity [14]. Consequently, patient blood manage-
ment calls for tighter transfusion thresholds [15]. Transfusion itself, however, only pre-
vents definitive diagnosis and management of anemia, again resulting in negative conse-
quences for patients recovering from surgery. Thus, to achieve the goal of patient blood 
management, anemia has to be taken out of the equation by addressing its causes. 
During a hospital stay, 25% of patients develop relevant anemia [16]. This is called 
Hospital-Acquired Anemia (HAA). It is very common that patients having normal hemo-
globin values upon admission develop anemia over the course of hospitalization [17]. The 
incidence ranges from approximately 25–75% prior to discharge using the nadir hemoglo-
bin values during hospitalization. Potential etiologies for HAA are iatrogenic blood loss 
from phlebotomy [18–22] or “anemia of chronic disease” induced by acute phase reactions 
stimulated by interleukins activating hepcidin synthesis [23–25]. HAA has been postu-
lated to be a hazard of hospitalization that is potentially preventable [8]. Early diagnostic 
of anemia in critical care units is needed, to differentiate between HAA and other causes 
of anemia. 
3. Causes of Anemia 
Anemia is defined by the World Health Organization (WHO) as a decrease in hemo-
globin concentration in the blood below certain sex- and age-specific levels—specifically 
<13 g/dL (8 mmol/L) for men, Hb <12 g/dL (7.4 mmol/L) for women and <11 g/dL (6.8 
mmol/L) for pregnant women [26]. There is, however, some discussion as to whether the 
statistically lower average concentrations of HGB in women indeed justify a distinct lower 
reference limited and do not in fact describe conditions that should better receive treat-
ment. 
Anemia can be caused either by decreased production of hemoglobin or red blood 
cells or by increased consumption and excessive blood loss or red blood cell destruction. 
Decreased of production can involve anything from erythropoietin or vitamin B12 insuf-
ficiency to absolute or functional iron deficiency. 
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3.1. Iron Deficiency Anemia 
Iron deficiency is the most common cause of anemia [27], but reduced iron levels and 
low iron availability have multiple negative effects, and may be responsible for fatigue, 
organ dysfunction and other disorders [28,29]. Iron is not just a component of hemoglobin, 
but also of myoglobin, and thus, patients with severe heart failure are at particular risk 
[30,31]. 
If iron deficiency is caused, for example, by malnutrition, first the iron stores will be 
depleted, with all iron going directly to erythropoiesis, leading to low ferritin. As the iron 
deficiency worsens, transferrin saturation decreases as not enough iron can be mobilized 
to meet demands. Eventually, erythropoiesis will become iron deficient, with new reticu-
locytes not being provided enough hemoglobin (reduced reticulocyte hemoglobin). Fi-
nally, as more and more fully hemoglobinized red blood cells die off and are replaced 
with hypochromic ones, anemia fully manifests in a decrease in overall blood hemoglobin 
and microcytosis, until in the end the overall number of red blood cells decreases, too. 
3.2. Anemia of Inflammation (ACD, Anemia of Chronic Disease)/Hospital-Acquired Anemia 
However, certain conditions can block iron stores from releasing iron, leading to de-
ficient erythropoiesis in the presence of filled iron stores. This can be found in patients 
with chronic disease, e.g., cancer, with rheumatic or other inflammatory diseases, or with 
chronic infections. While significant inflammation can also lead to suppression of eryth-
ropoietin production or sensitivity, in most cases, anemia of chronic disease or of inflam-
mation is brought about via interference with iron metabolism. In these cases, pro-inflam-
matory cytokines are released, among which interleukin 6 leads to a subsequent release 
of hepcidin by the liver. 
Hepcidin regulates iron metabolism by binding to the iron export channel ferroportin 
and causing its internalization [32]. Ferroportin is found both on the basolateral surface of 
enterocytes of the intestinal tract and in macrophages. Hepcidin thus blocks both the re-
lease of dietary iron into the hepatic portal system by the gut, and the uptake of dietary 
iron, as well as the release of iron stored in macrophages and thus the functional capacity 
of iron already stored in the body. During conditions in which the hepcidin level is abnor-
mally high, such as inflammation, serum iron falls due to iron trapping within macro-
phages and liver cells and decreased intestinal iron absorption. This typically leads to 
functional iron deficiency due to an inadequate amount of serum iron being available for 
developing red blood cells. When the hepcidin level is abnormally low—as in hemochro-
matosis—iron overload occurs due to increased ferroportin- mediated iron efflux from 
storage and increased gut iron absorption [32]. The treatment of an iron deficiency will 
thus depend on the hepcidin levels that are present. Oral treatment will be unlikely to be 
effective if hepcidin is blocking enteral absorption, in which case parenteral iron treatment 
would be called for. Measuring hepcidin itself, however, is complex and not widely done. 
Instead, CRP is often used as a proxy to indicate the presence of inflammation. 
3.3. Using Diagnostics to Differentiate between Iron Deficiency Anemia and Anemia of Chronic 
Diseases to Identify Adequate Treatment 
The complex differential diagnostics of iron deficiency has led to a host of different 
parameters. Among the parameters traditionally used to assess iron deficiency are the 
soluble iron in the blood, the iron in ferritin storage, transferrin, and transferrin saturation. 
These have substantial disadvantages in terms of reliability, especially during an acute 
phase reaction and in the presence of anemia due to chronic diseases (ACD) (Table 1). On 
the other hand, due to the lifetime of red blood cells (~120 days), parameters measuring 
directly characteristics of the bulk of red blood cells and overall hemoglobin have a large 
delay in their response. 
Table 1. Overview of iron deficiency parameters. 
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RET-He Iron deficient erythropoiesis 
Functional availa-
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Not available from 
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CKD = chronic kidney disease; EPO = erythropoietin; sTfR = soluble transferrin receptor 
Ret-He = mean reticulocyte hemoglobin 
Serum iron has high variability between and within individuals and is neither sensi-
tive nor specific. Ferritin is generally seen as the gold standard for iron deficiency but is 
in fact specific for iron storage deficiencies: While a low value indicates a lack of storage 
iron, ferritin is an acute phase reactant, and a normal or even high value can mask insuf-
ficient availability of iron for erythropoiesis. [33] (p. 1) Transferrin illustrates the demand 
for iron but can be depressed in chronic inflammation. The same holds true for its satura-
tion. The soluble transferrin receptor or the sTfR-Fe index are likewise subject to acute 
phase reaction to some degree but are particularly problematic in that they are not well 
standardized and expensive, and as such not available in some smaller hospitals. Thus, 
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the traditional parameters, despite offering elaborate options, are not ideally suited to giv-
ing a reliable overview of the iron status for erythropoiesis, especially during the acute 
phase. An alternative was thus needed. 
4. Reticulocyte Hemoglobin
Reticulocyte hemoglobin (measured as RET-He or CHr, proprietary names of the 
manufacturers of haematology analyzers Sysmex (Kobe, Japan) and Siemens Healthineers 
(Erlangen, Germany), respectively) [34,35] is a measurement of the mean hemoglobin con-
tained in reticulocytes, the immature red blood cells freshly released from the bone mar-
row. RET-He (reticulocyte hemoglobin equivalent) is derived from forward scatter of the 
reticulocyte population identified in the optical RBC scattergram. These are the cells with 
the highest side fluorescence obtained by a nucleic acid stain. As reticulocytes are the di-
rect products of erythropoiesis, they offer an almost immediate snapshot of the availabil-
ity of iron, and as they mature within a few days, they are not drowned out by older cells 
produced during a different iron status as is the case for mature red blood cells. The retic-
ulocyte count itself is a good parameter for the quantitative aspect of erythropoiesis, but 
hemoglobinization of reticulocytes gives additional information about quality of erythro-
poiesis directly reflecting the hemoglobinization. RET-He can thus detect a latent subclin-
ical iron deficiency even before the manifestation of full iron deficiency anemia [36,37]. As 
it directly reflects the erythropoiesis, the parameter is not confounded by acute phase re-
action [38,39]. It responds quickly (within about 2 days), is accurate [40], and is inexpen-
sive, as it is part of a blood count from specific proprietary hematology analyzers. This 
makes it a much more practical and available solution for measuring iron availability to 
erythropoiesis than the reference method involving bone marrow aspiration and Prus-
sian-Blue staining. The two main parameters of reticulocyte hemoglobin measurement 
have been shown to be highly correlated and concordant [35,41] and can be used inde-
pendently of the specific solution mentioned in guidelines. 
While it has long been known that anemia is associated with the need for blood trans-
fusion and greater mortality in surgical patients, it has more recently been shown that the 
same holds true for critically ill patients with low mean reticulocyte hemoglobin (<29 pg) 
[42]. 
But what role can reticulocyte hemoglobin play in anemia diagnostics? 
The use of reticulocyte hemoglobin, possibly plotted against an index calculated from 
sTfR/log ferritin (Figure 1), if other clinical chemistry parameters are desired despite the 
drawbacks mentioned, was proposed by Thomas & Thomas [38] as far back as 2002, with 
the goals being to distinguish between absolute and functional iron deficiency and to track 
iron repletion. It thus stands to reason that reticulocyte hemoglobin should also be able to 
play a role as a more accurate, sensitive, timely and inexpensive option to know which 
anemia to treat with iron. 
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Figure 1. Modified Thomas plot [38]. Characterization (A) and monitoring (B) of anemia based on reticulocyte hemoglobin 
and the sTfR/log ferritin index. In (B), an initial functional iron deficiency (1) is first treated with ESA and i.v. iron therapy 
(2). Subsequent focus on ESA therapy leads to reduction of storage iron to a borderline level, while hemoglobinization of 
reticulocytes is still normal (3), Ret-Hb = Ret-He = mean reticulocyte hemoglobin. 
5. Treatment
In patients with renal anemia, especially those undergoing hemodialysis, although the 
cause of anemia is generally an EPO deficiency, secondary ACD can still lead to iron-re-
stricted erythropoiesis and interfere with therapy. Ferritin values can be normal or elevated, 
even when no iron is available. Reticulocyte hemoglobin measurement can show that iron 
is functionally deficient and not arriving in the bone marrow [33,43]. In this case, guidelines 
then recommend intravenous iron for dialysis patients. Reticulocyte hemoglobin can subse-
quently be used to track recovery of the iron supplied to erythropoiesis (Table 2) [43,44]. 
Table 2. Evaluation of iron deficiency in chronic kidney disease. 
Cellular assessment 
Hb < 11 g/dL 
RBC indices (MCH, MCHC, MCV)  
White blood cell and differential count 
Platelet and reticulocyte count 
Iron assessment 
Hypochromic cells % (if sample < 6 h 
old) Reticulocyte Hb (RET-He)  
Serum ferritin  
C-reactive protein
Iron therapy targets 
Hypochromic cells < 6%  
Reticulocyte Hb (RET-He) > 29 pg 
Ferritin > 100 µg/L  
TSAT > 20% 
Hb = mean hemoglobin, RBC = red blood cells, MCH = mean corpuscular hemoglobin, MCHC = 
mean corpuscular hemoglobin concentration, MCV = mean corpuscular volume, Reticulocyte Hb = 
Ret-He = mean re ticulocyte hemoglobin, TSAT = transferrin saturation, 
Anemia of chronic disease is the second most common cause of anemia [45]. As in 
patients undergoing dialysis, chronic inflammation or malignant diseases can cause func-
tional iron deficiency. Iron will again be unavailable, with the unwanted side effect of 
depriving the bone marrow of iron, too. 
Reticulocyte hemoglobin has been shown to be a reliable diagnostic marker even un-
der these conditions that iron supply is limited for the bone marrow for erythropoiesis 
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[46] and can track the response to therapy. Its use, alone or in the form of the plot men-
tioned above, has been suggested or advised in reviews and recommendations for the
diagnosis and management of anemia of chronic disease [47] as well as for determining
the usefulness of iron administration.
In the case of absolute iron deficiency, ferritin and reticulocyte hemoglobin can be 
expected to both be low. As iron demand is high and there is no present need to store iron, 
reticulocyte hemoglobin can track the response to iron repletion therapy more directly. 
Reticulocyte hemoglobin can thus help to uncover the cause of the anemia and to 
identify the main factors inhibiting erythropoiesis [48]. Regardless of the cause of the ane-
mia, reticulocyte hemoglobin can quickly track the success of therapy and, together with 
the regular full blood count it is measured alongside with, clear the patient for surgery. 
Depending on the cause of the anemia, simple oral iron supplementation may be suf-
ficient if surgery is not urgent. In patients with preexisting chronic inflammatory condi-
tions, i.v. iron may be necessary. 
6. Postoperative Iron Deficiency
Diagnosis of postoperative iron deficiency can be even more difficult than that of 
preoperative deficiency since ferritin levels may be elevated as part of the acute phase 
response after surgery [49]. As a result, RET-He is recommended as a reliable parameter 
to assess iron availability in the management of patients with postoperative anemia after 
major surgical procedures [11]. Even in acute surgical patients, removing any bottlenecks 
can help prevent major postoperative complications, and giving iron one day before or 
even during surgery has been shown to improve postoperative erythropoiesis [50,51]. 
Therapeutic interventions to counteract the anemic condition should be started immedi-
ately upon classification and RET-He can help show whether iron or ESA are needed. In 
some cases of severe anemia, especially in the presence of comorbidities, transfusions may 
of course still be necessary. For iron treatment, intravenous iron is generally indicated, as 
an inflammatory response to the surgery is likely to prevent the availability of iron stores 
postoperatively. 
The use of reticulocyte hemoglobin can provide an inexpensive snapshot of the status 
of erythropoiesis, ensuring that even latent iron deficiency is recognized before surgery. 
Measures to mitigate the iron deficiency can then be implemented in a timely fashion, 
thereby also reducing the risk of adverse events due to RBC concentrate treatment during 
surgery. 
7. Patient Blood Management (PBM) and Iron Deficiency
For Germany alone, modelling suggests that in the context of iron deficiency anemia, 
implementation of rigorous preoperative anemia management could save €536 million in 
direct costs and a further €503 million through reduced length of stay of elective surgery 
patients, for a total of more than €1000 million, at the same time avoiding 3036 hospital 
deaths. Meanwhile, the costs of implementing preoperative anemia management were 
estimated to be €10–17 million, depending on the iron dosage used [52]. 
However, the preoperative management of anemia in the context of Patient Blood 
Management is currently practiced in a very heterogeneous way, even in countries with 
highly developed healthcare systems [53]. Lack of knowledge and awareness about the 
impact on outcomes of anemia and iron deficiency, and the complicated pathway to assess 
and treat anemia, may be a contributing factor. Reticulocyte hemoglobin content or equiv-
alent, on the other hand, could be incorporated into routine preoperative evaluation with 
a regular blood count, without requiring additional blood samples and only minimal 
added costs, providing invaluable information on most causes of anemia, and facilitating 
management. It therefore has the potential to become a fixed parameter in PBM and ERAS. 
8. Potential Role of Ret-He in Treatment of Iron Deficiency in Septic Patients
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Iron is a key factor in microbial growth and the downregulation of iron uptake and 
transport by hepcidin thought to be part of an immune response [54]. Consequently, there 
are some who oppose iron treatment in sepsis patients for fear of facilitating microbial 
growth, preferring to use packed red blood cells when anemia becomes critical. However, 
not only are some bacteria not affected by this type of iron restriction, but some are also 
capable of using heme as a source of iron [55], making transfusion in that aspect function-
ally similar to iron therapy. Moreover, erythrocyte concentrate therapy is independently 
associated with a significant risk of complications and mortality. The question arises as to 
whether reticulocyte hemoglobin, perhaps in association with other parameters, could 
help fine-tune iron treatment so that it meets the needs of the bone marrow but avoids 
fostering bacterial growth. Tracking iron replenishment in erythropoiesis by comparing 
the hemoglobinization of the mature erythrocytes, measured through the same technol-
ogy as that of the reticulocytes, may indicate when iron therapy can be stopped, but also 
illustrate that iron is being sequestered in the first place. The corresponding parameter for 
this difference has been dubbed Delta-He by Sysmex. It is calculated by subtracting RBC-
He from RET-He. RBC-He is the haemoglobin content of erythrocytes and therefore 
roughly comparable to MCH but measured with the same technique as RET-He. Together 
with reticulocyte hemoglobin, it can also be used to obtain a much more differentiated 
assessment of anemia, as certain constellations are characteristic for different underlying 
causes [56] (Figure 2). 
 
Figure 2. Hema-plot (adapted from Weimann et al. [56]) Characterization of anemia based on retic-
ulocyte hemoglobin (RET-He) and the difference between it and the hemoglobinization of mature 
erythrocytes (Delta-He). 
9. Outlook 
Combining these reticulocyte-related parameters with a more complex characteriza-
tion of white blood cells may provide a better idea as to what type of pathogen is causing 
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the inflammation. Variations in side scatter and fluorescence of white blood cells can re-
flect the activation and reactivity of lymphocytes, monocytes or neutrophils. This would 
provide peace of mind when it comes to starting i.v. iron. For the time being, the proposed 
Intensive Care Infection Score (ICIS) can help differentiate bacterial infection from non-
infectious systemic inflammation [57]. The ICIS comprised five blood-cell derived param-
eters that characterize the early innate immune response: (I) mean fluorescence intensity 
of mature (segmented) neutrophils; (II) difference in haemoglobin concentration between 
newly formed and mature red blood cells; (III) total segmented neutrophil count; (IV) an-
tibody secreting lymphocyte count; (V) immature granulocyte count [57]. 
Initial studies of the ICIS that include the parameter Delta-He have been promising 
[57–59]. The difference between hemoglobinization of mature erythrocytes and reticulo-
cytes is important in this context (Figure 3). 
Figure 3. Example for Delta-He in a sepsis patient. The response to a change in antibiotic therapy 
is already apparent in the increase in Delta-He after 12 h - Other parameters respond much more 
slowly. 
In fact—and this leads us to the current pandemic - a similar score also including 
RET-He and Delta-He has recently been proposed as a prognostic tool in COVID-19 infec-
tions [60]. The aim of this study was to develop a prognostic score (based on multiple 
hematocytometric parameters) to predict during the first three days after presentation, 
which patients will recover without ventilation or deteriorate within a two-week time 
frame. Here, too, Delta-He has an important contributing role in score composition, show-
ing markedly different behavior in critical vs. non-critical patients (Figure 4). 




Figure 4. Delta-He in COVID-19 patients. Difference between critical (CI) and non-critical patients 
(NC). 
As for Patient Blood Management, already in 2006 orthopedic surgeons and clinical 
chemists in the Netherlands published a protocol optimizing the treatment of both pre- 
and postoperative anemia by detecting iron deficiency using RET-He [61]. Over the course 
of the previous years, this protocol had allowed them to reduce the annual number of 
packed red blood cells needed for major hip and knee surgeries by 83% through the stra-
tegic administration of iron sucrose in patients in whom RET-He indicated iron deficiency. 
More recently, preoperative anemia walk-in clinics have been established at several 
hospitals in Germany. In one of them, use of RET-He was tested and eventually adopted 
as a routine parameter to screen for anemia before orthopedic surgery [62]. Including a 
score to detect infection generated from the same hematology analyzers in such protocols 
may, in the end, also resolve concerns about iron therapy in cases where severe infection 
may be suspected. 
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